Gag-Pol polyprotein


  • Accession: P03369
  • Swissprot: POL_HV1A2
  • Organism: Human immunodeficiency virus type 1 group M subtype B (isolate ARV2/SF2)
  • Gene: gag-pol
  • Target class: Polyprotein

Drug Relations:

a carbocyclic nucleoside with potent selective anti-HIV activity; structure given in first source Bioactivity details MOA
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Bioactivity details MOA
Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. Efavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. HIV-2 RT and human cellular DNA polymerases alpha, beta, gamma, and delta are not inhibited by efavirenz. Bioactivity details MOA
HIV-1 reverse transriptase inhibitor; an anti-HIV agent Bioactivity details MOA
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. Bioactivity details MOA
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Bioactivity details MOA
tenofovir disoproxil
Tenofovir disoproxil fumarate is the fumarate salt of the prodrug tenofovir disoproxil. Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate (nucleotide) analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate has an intracellular half-life of 10 hours in activated and 50 hours in resting peripheral blood mononuclear cells (PBMCs). Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of cellular polymerases alpha, beta, and gamma. At concentrations of up to 300 umol/l, tenofovir has also shown no effect on the synthesis of mitochondrial DNA or the production of lactic acid in in vitro assays. Bioactivity details MOA